WO2009089448A1 - Composés thérapeutiques disulfure pour traiter la douleur et les diabètes - Google Patents

Composés thérapeutiques disulfure pour traiter la douleur et les diabètes Download PDF

Info

Publication number
WO2009089448A1
WO2009089448A1 PCT/US2009/030594 US2009030594W WO2009089448A1 WO 2009089448 A1 WO2009089448 A1 WO 2009089448A1 US 2009030594 W US2009030594 W US 2009030594W WO 2009089448 A1 WO2009089448 A1 WO 2009089448A1
Authority
WO
WIPO (PCT)
Prior art keywords
pain
compound
diabetes
mammal
therapeutic
Prior art date
Application number
PCT/US2009/030594
Other languages
English (en)
Inventor
Gyorgy F. Ambrus
Mark P. Rubino
Todd M. Heidelbaugh
Phong X. Nguyen
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Priority to EP09701462A priority Critical patent/EP2242748A1/fr
Publication of WO2009089448A1 publication Critical patent/WO2009089448A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • These compounds may be administered to a mammal to treat pain, including visceral pain, pain caused by irritable bowel syndrome, neuropathic pain, and pain caused by dyspepsia.
  • These compounds may be administered to a mammal to treat symptoms of diabetes, including hyperglycemia, hyperlipidemia, decreased levels of blood insulin, and hypertriglyceridemia.
  • a dosage form such as pill, tablet, or capsule for oral administration, or a liquid for injection, is prepared containing the compound, and the dosage form is administered to a mammal needing the treatment.
  • a dosage form such as pill, tablet, or capsule for oral administration, or a liquid for injection
  • a dosage form is prepared containing the compound, and the dosage form is administered to a mammal needing the treatment.
  • suitable dosage forms are known in the art.
  • U.S. Patent No. 7,141,597 describes suitable methods.
  • the dose may vary depending upon the mammal being dosed and the particular condition being treated. A person of ordinary skill in the art can determine the dose appropriate for the situation. For example, for humans, a dose of from about 10 to about 100 mg, given twice a day is contemplated.
  • “treat,” “treating,” or “treatment” refers to the diagnosis, cure, mitigation, treatment, or prevention of disease or other undesirable condition.
  • reference to a compound should be construed broadly to include compounds, pharmaceutically acceptable salts, prodrugs, tautomers, alternate solid forms, non-covalent complexes, and combinations thereof, of a chemical entity of a depicted structural formula or chemical name.
  • a pharmaceutically acceptable salt is any salt of the parent compound that is suitable for administration to an animal or human.
  • a pharmaceutically acceptable salt also refers to any salt which may form in vivo as a result of administration of an acid, another salt, or a prodrug which is converted into an acid or salt.
  • a salt comprises one or more ionic forms of the compound, such as a conjugate acid or base, associated with one or more corresponding counter-ions.
  • Salts can form from or incorporate one or more deprotonated acidic groups (e.g. carboxylic acids), one or more protonated basic groups (e.g. amines), or both (e.g. zwitterions).
  • a prodrug is a compound which is converted to a therapeutically active compound after administration. For example, conversion may occur by hydrolysis of an ester group or some other biologically labile group. Prodrug preparation is well known in the art. For example, “Prodrugs and Drug Delivery Systems,” which is a chapter in Richard
  • [ll]Tautomers are isomers that are in rapid equilibrium with one another.
  • tautomers may be related by transfer of a proton, hydrogen atom, or hydride ion.
  • Alternate solid forms are different solid forms than those that may result from practicing the procedures described herein.
  • alternate solid forms may be polymorphs, different kinds of amorphous solid forms, glasses, and the like.
  • Non-covalent complexes are complexes that may form between the compound and one or more additional chemical species that do not involve a covalent bonding interaction between the compound and the additional chemical species. They may or may not have a specific ratio between the compound and the additional chemical species.
  • Examples might include solvates, hydrates, charge transfer complexes, and the like.
  • One embodiment is a compound represented by the structure:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des composés représentés par la formule. Des procédés thérapeutiques, des compositions et des médicaments qui leur sont liés sont également révélés.
PCT/US2009/030594 2008-01-11 2009-01-09 Composés thérapeutiques disulfure pour traiter la douleur et les diabètes WO2009089448A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09701462A EP2242748A1 (fr) 2008-01-11 2009-01-09 Composés thérapeutiques disulfure pour traiter la douleur et les diabètes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2045808P 2008-01-11 2008-01-11
US61/020,458 2008-01-11

Publications (1)

Publication Number Publication Date
WO2009089448A1 true WO2009089448A1 (fr) 2009-07-16

Family

ID=40395099

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/030594 WO2009089448A1 (fr) 2008-01-11 2009-01-09 Composés thérapeutiques disulfure pour traiter la douleur et les diabètes

Country Status (2)

Country Link
EP (1) EP2242748A1 (fr)
WO (1) WO2009089448A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059721A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Nonsedating alpha-2 agonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059721A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Nonsedating alpha-2 agonists

Also Published As

Publication number Publication date
EP2242748A1 (fr) 2010-10-27

Similar Documents

Publication Publication Date Title
US10799492B2 (en) Deuterated analogs of pridopidine useful as dopaminergic stabilizers
CN112479996B (zh) 吡啶氮氧化合物及其制备方法和用途
CN1136193C (zh) 酰胺衍生物或其盐类
DE69737980T2 (de) Nitrosierte und nitrosylierte alpha-adrenorezeptoreantagonisten, zubereitungen und deren verwendungen
RU2007101653A (ru) Производные 1-азабицикло[3.3.1]нонанов
US11434205B2 (en) Substituted imidazole carboxylate derivatives and the use thereof
CN105412092B (zh) 用于降低眼内压的[3-(1-(1h-咪唑-4-基)乙基)-2-甲基苯基]甲醇的酯前药
JP2006500403A (ja) キノリルプロピルピペリジン誘導体およびその抗菌性物質としての使用
JP2007515447A5 (fr)
RU2004136853A (ru) (s)-4-амино-5-хлор-2-метокси-n-[1-[1-(2-тетрагидрофурилкарбонил)-4- пиперидини лметил]-4-пиперидинил]бензамид, способ его получения, содержащая его фармацевтическая композиция и промежуточное соединение для его получения
JP3839665B2 (ja) 置換２−ベンジルアミノ−２−フェニル−アセトアミド化合物
EP3930722A1 (fr) Traitement avec des modulateurs de p2x3
WO1996031470A1 (fr) Nouveaux composes heterocycliques
CN1033454C (zh) 4-[(2-苯并噻唑基)甲氨基]-α-[(3，4-二氟苯氧基)甲基]-1-哌啶乙醇的制备方法
JP5571072B2 (ja) アルファアドレナリン介在症状の治療方法
EP2242748A1 (fr) Composés thérapeutiques disulfure pour traiter la douleur et les diabètes
CN114075123B (zh) 苄胺类衍生物及其制备方法与用途
CN115677507A (zh) 氟比洛芬衍生物及其在药物中的应用
US8168632B2 (en) Bicyclic amide derivatives for the treatment of respiratory disorders
JPH05213957A (ja) 新規なスピロピロリジンイミダゾリン誘導体および新規なアミノピロリジンカルボン酸誘導体並びに該化合物を有効成分とする鎮けい剤
WO2018039641A1 (fr) Procédés et composés pour le traitement de troubles d'utilisation d'alcool et de maladies associées
EP3512832A1 (fr) Antagonistes opioïdes kappa de tétrahydroisoquinoline
EP2414323B1 (fr) Dérivés d'aminocyclobutane ou d'aminocyclobutène, leur procédé de préparation et leur utilisation comme produits médicaux
JP3681770B2 (ja) 老年性痴呆症又はアルツハイマー病治療剤
CN86102285A (zh) 新的二胺衍生物的制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09701462

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009701462

Country of ref document: EP